The Hospitals As Naloxone Distribution Sites (HANDS) Act adds a new Medicare benefit and amends Medicaid and TRICARE law so that opioid overdose reversal drugs furnished at hospital discharge — intranasal or intramuscular formulations — are provided without patient cost-sharing beginning January 1, 2026. The drug must be furnished by an attending clinician to an inpatient or an individual leaving an emergency department or ambulatory surgical center, after a clinician determines the person is at risk and provides administration instructions.
This is a targeted, program-level approach to remove a financial barrier to post-discharge naloxone access. For compliance officers and hospital administrators the bill creates new billing lines, reimbursement rules, and regulatory guidance duties; for payers it creates a mandatory zero cost-sharing obligation and integrates these drugs into Medicaid rebate and benefit structures.
The bill also preserves provider discretion by expressly declining to mandate that a clinician must furnish the drug.
At a Glance
What It Does
Establishes a preventive opioid overdose reversal drug benefit, defines eligible drugs and clinical settings, requires zero cost-sharing across Medicare, Medicaid benchmark/ABP plans, Medicare Advantage, and TRICARE, and instructs FDA and HHS to issue implementation guidance within one year.
Who It Affects
Hospitals, critical access and rural emergency hospitals, emergency departments and ambulatory surgical centers; clinicians who discharge patients; Medicare and Medicaid programs and plans; TRICARE; and hospital billing and pharmacy operations.
Why It Matters
Removes out-of-pocket cost barriers at a high-opportunity point of care (discharge), forces operational changes in hospital dispensing and billing, and folds these drugs into federal coverage and rebate systems—shifting practical and budgetary responsibilities to public programs and hospital workflows.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The HANDS Act creates a new, narrowly tailored federal benefit for opioid overdose reversal drugs furnished at the point a patient leaves hospital care. The bill adds a new definition to the Social Security Act for a “preventive opioid overdose reversal drug” — either intranasal or intramuscular naloxone or equivalent — and limits eligible encounters to inpatients of hospitals (including critical access and rural emergency hospitals) and patients leaving emergency departments or ambulatory surgical centers.
A clinician must determine the individual is at risk for overdose and provide the drug at discharge together with administration instructions.
On the payment side, the bill amends Medicare statute to require payment without patient cost-sharing for these drugs furnished on or after January 1, 2026. For fee-for-service Medicare the statutory language directs payment equal to 100 percent of the lesser of actual charges or the amount determined under the relevant payment rule.
It also prevents application of the Medicare deductible to these items and bars cost-sharing for Medicare Advantage plans. For Medicaid, the bill makes coverage of these preventive drugs mandatory in state plans and in alternative benefit (benchmark) plans, adds the drugs to the list of medical assistance items, and brings them within the Medicaid drug rebate framework by deeming them prescribed drugs for rebate purposes.The bill amends TRICARE to eliminate cost-sharing for the same preventive drugs for eligible beneficiaries.
Recognizing practical hurdles, it orders the FDA to issue guidance for state boards (pharmacy, nursing, medicine) and requires HHS to issue hospital billing guidance within one year of enactment. Finally, the statute includes a rule of construction clarifying that nothing in the Act forces any provider to furnish the drug — the furnishing decision remains a clinical choice.
The Five Things You Need to Know
Effective date: coverage and no-cost-sharing rules apply to preventive opioid overdose reversal drugs furnished on or after January 1, 2026.
Definition and setting: the law covers intranasal or intramuscular overdose reversal drugs furnished at discharge to inpatients or to patients leaving an emergency department or ambulatory surgical center after a clinician determines they are at risk and provides administration instructions.
Medicare payment mechanics: fee-for-service Medicare payments for these drugs are set at 100% of the lesser of actual charges or the amount under section 1842(o), and the Medicare deductible may not be applied.
Medicaid and rebates: states must include these drugs in Medicaid state plans and alternative benefit plans; the statute brings them under the Medicaid drug rebate program by deeming them prescribed drugs for rebate calculation.
Implementation deadlines and limits: FDA and HHS must issue guidance within one year on state board rules and hospital billing, and the bill explicitly stops short of obligating any provider to dispense the drug.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Medicare benefit, definition, and cost‑sharing prohibition
This cluster of amendments adds a new enumerated benefit to section 1861 for “preventive opioid overdose reversal drugs,” defines the term (intranasal or intramuscular, furnished by specified clinicians at discharge for at-risk patients and accompanied by instructions), and updates section 1833 to require payment at 100% and to bar application of the Medicare deductible and other beneficiary cost-sharing. Practically, hospitals and billing departments will need to identify the correct billing path and reconcile how this standalone payment interacts with existing inpatient prospective payment systems and outpatient drug payment rules.
Medicare Advantage cost-sharing ban
The bill amends the Medicare Advantage benefit design language to list preventive opioid reversal drugs among items for which plans may not impose cost-sharing. Plans will have to amend benefit structures and PDP/MA communications to reflect the zero cost-sharing rule for qualifying furnished drugs, and plan auditors will need new compliance checks.
Medicaid mandatory coverage, inclusion, and rebate treatment
Multiple Medicaid provisions (1902(a)(10)(A), 1937(b), 1905(a)) are changed to make coverage of these preventive drugs mandatory in state plans and in alternative benefit packages beginning January 1, 2026. The bill also amends the rebate statute (1927) to include these drugs and expressly deems them prescribed drugs for rebate calculations. States must therefore include them in formularies/benefit designs with no deductions or cost-sharing and coordinate rebate tracking and reporting for units furnished at discharge.
TRICARE cost-sharing prohibition
Adds preventive opioid overdose reversal drugs to the list of items for which TRICARE beneficiaries will not pay cost-sharing as of January 1, 2026. The Defense Health Agency will need to update TRICARE policy and claims adjudication systems to exempt these items from beneficiary copays and cost-shares.
Regulatory guidance and provider discretion
Directs the FDA to issue guidance to state professional boards aimed at reducing regulatory barriers to hospital-based dispensing and requires HHS to issue hospital billing guidance within one year. The bill also includes a rule of construction that does not force any provider to furnish the drug; furnishing remains subject to clinician judgment and local policies. These provisions place practical implementation on agencies while preserving clinical autonomy.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Hospital patients at discharge who are determined by a clinician to be at risk for opioid overdose — they face no out-of-pocket charge for a naloxone product provided at discharge, improving immediate access to a life-saving antidote.
- Household members and caregivers of at-risk patients — easier access to take-home naloxone increases the chance of timely bystander administration if an overdose occurs after discharge.
- Public payers and public health programs focused on post-discharge overdose prevention — the law standardizes access points for naloxone distribution through hospitals and integrates the intervention into federal coverage frameworks.
- Rural and critical access hospitals with higher overdose mortality risk — the definition explicitly covers these settings, making them eligible to furnish and seek reimbursement under federal programs.
Who Bears the Cost
- Medicare (federal trust funds) and TRICARE (Defense Health Agency budgets) — federal programs will absorb the payments now barred from beneficiary cost-sharing and may see increased utilization.
- State Medicaid programs — while coverage is mandatory, states will need to adjust formularies, claims systems, and budget forecasts (though federal matching and rebates apply, administrative and program costs rise).
- Hospitals and hospital pharmacies — they must stock appropriate formulations, update discharge workflows, train clinicians, and implement billing processes to capture the new payment; smaller facilities may face operational strain.
- Drug manufacturers — inclusion in the Medicaid rebate program and classification as prescribed drugs could reduce net revenue per unit and increase reporting obligations.
Key Issues
The Core Tension
The bill balances two legitimate objectives — removing patient financial barriers to naloxone at a critical discharge point versus the fiscal and operational burdens this shifts onto federal payers, state Medicaid programs, and hospital systems — and leaves unresolved how to reconcile standardized federal coverage with variable clinical judgement and complex hospital billing ecosystems.
Implementation creates several practical and legal frictions the statute does not fully resolve. First, the statute fixes payment language for Medicare but does not reconcile how furnishing a discharge naloxone kit interacts with bundled inpatient payments (DRGs), outpatient department APCs, or ambulatory surgical center payment rules; hospitals will need HHS guidance and payers will have to define appropriate claim lines.
Second, the bill confines the benefit to drugs furnished at discharge by clinicians in specific hospital settings; it does not address outpatient primary care, community distribution programs, or pharmacy-based standing orders, leaving gaps where many naloxone distributions currently occur. Third, folding these items into Medicaid rebates and deeming them prescribed drugs is administratively sensible but creates reporting and unit-tracking complexity for products dispensed in the hospital rather than through a traditional pharmacy fill.
Operationally, hospitals may face stock-management and training burdens, and clinicians may vary in risk assessment thresholds — the law preserves clinician discretion, which supports individualized care but risks uneven access across facilities and regions. The one-year guidance deadlines for FDA and HHS push much of the implementation detail to agencies, but guidance is nonbinding and may come too late for operational planning ahead of the statutory start date.
Finally, the statute does not change malpractice or liability regimes around furnishing naloxone at discharge; providers and hospitals will want clarity on documentation, consent, and post-dispensing follow-up protocols.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.